Ikarovec to Advance Pipeline With Exclusive Worldwide Option to VectorBuilder’s Intravitreal Capsid Technology

NORWICH, England & CHICAGO--(BUSINESS WIRE)-- #BioTechNews--Ikarovec Ltd, which is developing dual-pathway gene therapies for vision-threatening retinal diseases, and VectorBuilder, a global leader in gene delivery technologies, have entered into an exclusive worldwide option agreement for VectorBuilder’s novel AAV capsid technology to be used in combination with Ikarovec’s gene therapy candidate IKAR-003 for intermediate age-related macular degeneration (AMD). Following successful further evaluation of the t